Stock Monitor: Syros Pharma Post Earnings Reporting

LONDON, UK / ACCESSWIRE / November 27, 2017 / Active-Investors issued a free report on Exelixis, Inc. (NASDAQ: EXEL), which is readily accessible upon registration at www.active-investors.com/registration-sg/?symbol=EXEL as the Company's latest news hit the wire. On November 21, 2017, the Company announced that the Phase-3 CELESTIAL trial results have been accepted as a late-breaking presentation at the 2018 American Society of Clinical Oncology's Gastrointestinal Cancers Symposium (ASCO-GI), which will be held January 18?20, 2018, in San Francisco. Sign up now for our free research reports at: www.active-investors.com/registration-sg.

Active-Investors.com is currently working on the research report for Syros Pharmaceuticals, Inc. (NASDAQ: SYRS), which also belongs to the Healthcare sector as the Company Exelixis. Do not miss out and become a member today for free to access this upcoming report at: www.active-investors.com/registration-sg/?symbol=SYRS.

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Exelixis most recent news is on our radar and we have decided to include it on our blog post. Today's free coverage is available at: www.active-investors.com/registration-sg/?symbol=EXEL.

Exelixis to Submit NDA to FDA for Cabozantinib for Advanced HCC Treatment

The Company plans to submit a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) in the first quarter of 2018 for cabozantinib as a treatment for patients with advanced Hepatocellular Carcinoma (HCC). In October 2017, the FDA determined Exelixis' sNDA for CABOMETYX® for patients with previously untreated advanced Renal Cell Carcinoma (RCC) to be sufficiently complete to permit a substantive review.

Exelixis' Phase-3 CELESTIAL Trial of Cabozantinib Met Primary Endpoint of Overall Survival in Patients with Advanced HCC

On October 16, 2017, the Company's global Phase-3 CELESTIAL trial met its primary endpoint of overall survival (OS), with cabozantinib providing a statistically significant and clinically meaningful improvement in median OS compared to placebo in patients with advanced HCC. The independent data monitoring committee for the study recommended that the trial should be stopped for efficacy following review of the second planned interim analysis.

About Hepatocellular Carcinoma (HCC)

HCC is a primary malignancy of the liver and occurs predominantly in patients with underlying chronic liver disease and cirrhosis. HCC is the most common type of primary liver cancer in adults. As with any cancer, the treatment and prognosis of HCC vary depending on the specifics of tumor histology, size, how far the cancer has spread, and overall health.

About CELESTIAL

CELESTIAL is a randomized, double-blind, placebo-controlled study of cabozantinib versus placebo in patients with advanced HCC. The trial was designed to enroll 760 patients with advanced HCC who received prior sorafenib and may have received up to two prior systemic cancer therapies for HCC and had adequate liver function. Patients were randomized 2:1 to receive 60mg of cabozantinib once daily, or placebo, and were stratified based on etiology of the disease, geographic region, and presence of extrahepatic spread and/or macrovascular invasion.

About CABOMETYX® (Cabozantinib)

CABOMETYX is a prescription medicine used in the United States to treat people with advanced kidney cancer (renal cell carcinoma) whose cancer has spread, or grown, after treatment with other cancer medications. Side effects of CABOMETYX includes coughing up blood or blood clots, red or black stools, menstrual bleeding that is heavier than normal, or any unusual or heavy bleeding.

In March 2017, the FDA granted an orphan drug designation to cabozantinib for the treatment of HCC.

About Exelixis, Inc.

Founded in 1994, Exelixis is a commercially successful, oncology-focused biotechnology Company that strives to accelerate the discovery, development, and commercialization of new medicines for difficult-to-treat cancers. The Company is headquartered in San Francisco, California.

Stock Performance Snapshot

November 24, 2017 - At Friday's closing bell, Exelixis' stock was down 1.07%, ending the trading session at $25.85.

Volume traded for the day: 879.28 thousand shares.

Stock performance in the six-month ? up 33.59%; past twelve-month period ? up 56.76%; and year-to-date ? up 73.37%

After last Friday's close, Exelixis' market cap was at $7.73 billion.

Price to Earnings (P/E) ratio was at 52.43.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 0.3% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors